Core Insights - The company has undergone a comprehensive rebranding from N2OFF, Inc. to Nexentis Technologies Inc., reflecting its evolution into an innovative data-driven biotech firm focused on mitochondrial biology and precision oncology [1][2][4] - The rebranding is part of a strategic pivot that includes the integration of MitoCareX Bio Ltd., which is now a wholly-owned subsidiary, enhancing the company's drug discovery capabilities [3][6] Company Overview - Nexentis Technologies Inc. is focused on developing a pipeline of first-in-class small-molecule programs targeting mitochondrial SLC25 carriers, with applications in oncology and inflammatory metabolic diseases [3][5] - The company also maintains investments in solar energy assets through a Ready to Build (RTB) business model, which are considered non-core assets [1][3] Strategic Developments - The acquisition of MitoCareX on October 20, 2025, marked a significant shift from cleantech to biotechnology, establishing a foundation for the company's drug discovery strategy [6] - MitoCareX has validated its MITOLINE discovery platform, generating in vitro data that demonstrates anti-tumor activity and potential anti-inflammatory benefits, with markets for these indications projected to exceed $120 billion by 2030 [6] Research and Development Focus - The company is advancing a precision oncology and inflammation pipeline, targeting hard-to-treat resistant cancers and metabolic-inflammatory diseases, with plans for preclinical candidate nominations [6]